DexCom, Inc. (NASDAQ:DXCM) CEO Kevin R. Sayer sold 6,000 shares of DexCom stock in a transaction dated Wednesday, September 20th. The stock was sold at an average price of $69.34, for a total transaction of $416,040.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Kevin R. Sayer also recently made the following trade(s):

  • On Friday, August 11th, Kevin R. Sayer sold 6,000 shares of DexCom stock. The stock was sold at an average price of $69.77, for a total transaction of $418,620.00.
  • On Wednesday, July 12th, Kevin R. Sayer sold 6,000 shares of DexCom stock. The stock was sold at an average price of $71.86, for a total transaction of $431,160.00.

DexCom, Inc. (DXCM) traded up 0.71% during trading on Friday, reaching $69.99. 672,667 shares of the company’s stock traded hands. DexCom, Inc. has a 52-week low of $57.68 and a 52-week high of $94.79. The company’s 50 day moving average is $72.62 and its 200-day moving average is $73.86. The stock’s market cap is $6.06 billion.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Tuesday, August 1st. The medical device company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.07. DexCom had a negative net margin of 10.27% and a negative return on equity of 27.90%. The firm had revenue of $170.60 million for the quarter, compared to the consensus estimate of $166.54 million. During the same period in the prior year, the firm posted ($0.24) earnings per share. The company’s revenue for the quarter was up 24.3% on a year-over-year basis. On average, analysts anticipate that DexCom, Inc. will post ($0.78) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This news story was originally posted by American Banking News and is the property of of American Banking News. If you are viewing this news story on another publication, it was stolen and republished in violation of United States and international copyright laws. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2017/09/22/insider-selling-dexcom-inc-dxcm-ceo-sells-6000-shares-of-stock-2.html.

Institutional investors have recently made changes to their positions in the company. Advisor Group Inc. lifted its holdings in shares of DexCom by 104.9% in the second quarter. Advisor Group Inc. now owns 1,635 shares of the medical device company’s stock worth $119,000 after buying an additional 837 shares in the last quarter. Edmond DE Rothschild Holding S.A. purchased a new stake in shares of DexCom in the first quarter worth about $164,000. Brighton Jones LLC purchased a new stake in shares of DexCom in the first quarter worth about $204,000. IFP Advisors Inc lifted its holdings in shares of DexCom by 30.5% in the second quarter. IFP Advisors Inc now owns 2,431 shares of the medical device company’s stock worth $178,000 after buying an additional 568 shares in the last quarter. Finally, Independent Portfolio Consultants Inc. lifted its holdings in shares of DexCom by 0.4% in the second quarter. Independent Portfolio Consultants Inc. now owns 2,499 shares of the medical device company’s stock worth $183,000 after buying an additional 9 shares in the last quarter.

Several brokerages have weighed in on DXCM. Piper Jaffray Companies reiterated a “buy” rating and issued a $78.00 price objective on shares of DexCom in a research note on Wednesday, July 12th. Oppenheimer Holdings, Inc. set a $92.00 price objective on shares of DexCom and gave the stock a “buy” rating in a research note on Wednesday, August 2nd. BidaskClub cut shares of DexCom from a “sell” rating to a “strong sell” rating in a research note on Tuesday, August 1st. BMO Capital Markets reiterated an “outperform” rating and issued a $90.00 price objective (down previously from $105.00) on shares of DexCom in a research note on Tuesday, August 8th. Finally, Zacks Investment Research upgraded shares of DexCom from a “sell” rating to a “hold” rating in a research note on Monday, August 14th. Seven equities research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $86.87.

About DexCom

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Insider Buying and Selling by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with MarketBeat.com's FREE daily email newsletter.